NXNL1: A Potential Drug Target and Biomarker (G115861)

Target Name: NXNL1

NCBI ID: G115861

NXNL1

NXNL1: A Potential Drug Target and Biomarker

Nucleoredoxin like 1 (NXNL1) is a protein that plays a crucial role in the regulation of mitochondrial function and energy metabolism. It is a key component of the mitochondrial inner mitochondrial membrane, which is responsible for separating the mitochondria from the cytoplasm and facilitating the transfer of electrons during cellular processes such as cellular respiration. NXNL1 functions as a chaperone, helping to transport and fold proteins into their correct shapes.

Recent studies have identified NXNL1 as a potential drug target in the context of various diseases, including cancer, neurodegenerative diseases, and metabolic disorders. Its unique structure and function make it an attractive target for small molecule inhibitors, with potential therapeutic applications in a range of fields.

One of the key reasons for the interest in NXNL1 as a drug target is its involvement in the regulation of mitochondrial function. Mitochondria are critical for the production of energy by a process called cellular respiration, and are also involved in the detoxification of harmful substances and the regulation of various cellular processes. NXNL1 plays a key role in these processes, helping to maintain the proper functioning of the mitochondria and ensuring the delivery of oxygen and energy to the cells.

In addition to its role in mitochondrial function, NXNL1 has also been shown to be involved in the regulation of cellular signaling pathways. It has been shown to interact with a variety of molecules, including transcription factors, signaling proteins, and metabolic enzymes. This suggests that NXNL1 may be involved in the regulation of cellular processes that are not specifically targeted by currently available drugs.

The potential benefits of targeting NXNL1 are significant. If NXNL1 were to be successfully inhibited, it could have a range of therapeutic applications. For example, it could be used to treat neurodegenerative diseases such as Alzheimer's and Parkinson's disease, which are characterized by the progressive loss of brain cells. NXNL1 inhibition could also potentially be used to treat cancer, as it has been shown to be involved in the regulation of cellular signaling pathways that are often disrupted in cancer cells.

Another potential application of NXNL1 is the treatment of chronic energy poverty, a condition in which individuals are unable to access adequate energy due to a variety of factors, including poverty, lack of access to clean cooking fuels, and limited access to electrical power. NXNL1 inhibition could potentially be used to improve energy access and alleviate the symptoms of chronic energy poverty.

In conclusion, NXNL1 is a protein that plays a critical role in the regulation of mitochondrial function and energy metabolism. Its unique structure and function make it an attractive target for small molecule inhibitors, with potential therapeutic applications in a range of fields. Further research is needed to fully understand the role of NXNL1 in cellular processes and to develop effective inhibitors.

Protein Name: Nucleoredoxin Like 1

Functions: Plays an important role in retinal cone photoreceptor survival (PubMed:25957687). In association with glucose transporter SLC16A1/GLUT1 and BSG, promotes retinal cone survival by enhancing aerobic glycolysis and accelerating the entry of glucose into photoreceptors (PubMed:25957687). May play a role in cone cell viability, slowing down cone degeneration, does not seem to play a role in degenerating rods (By similarity)

The "NXNL1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about NXNL1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets